Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Vericel Corp director Kevin F. McLaughlin reported option exercises and related stock sales in Vericel common stock. On May 13, 2026, he exercised stock options to acquire a total of 7,000 shares of common stock, including 3,500 shares at an exercise price of $13.05 per share and 3,500 shares at $2.63 per share. On the same date, he sold 7,000 shares in open‑market transactions at prices of $32.82 and $32.83 per share. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock. The filing notes that the sales were automatic transactions executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Vericel Corp director Paul K. Wotton sold 10,000 shares of Common Stock in open-market transactions. On May 11, 2026, he reported selling 7,500 shares at $32.64 per share and 2,500 shares at $33.05 per share. These are discretionary, open-market sales of existing shares.
Issuer files a Form 144 notice to sell 7,000 shares of Common Stock. The filing lists sales through Fidelity Brokerage Services LLC on 05/13/2026 and identifies two issuances exercisable from options granted on 05/03/2017 and 05/02/2018, each for 3,500 shares.
The disclosed method is Cash Common and the listing venue is NASDAQ. The submission is a regulatory notice of intent to sell; the filing does not specify proceeds recipients beyond the broker information.
Vericel Corp’s Chief Financial Officer, Mara Joseph Anthony Jr, completed an automatic open-market sale of 5,000 shares of common stock at $40.50 per share. The transaction occurred on May 7, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following the sale, the CFO continues to hold 21,009 Vericel shares directly, including shares previously acquired through the company’s 2015 Employee Stock Purchase Plan. The filing reflects a planned, programmatic sale rather than a discretionary one-time trade.
Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported open-market sales of company common stock. On May 6, 2026, he sold 3,433 shares at $38.00 per share. On May 7, 2026, he sold an additional 1,422 shares at $40.50 per share.
The Form 4 states these transactions were made under an automatic Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged. After these sales, Siegal directly holds 1,118 shares of Vericel common stock, some of which were acquired through the company’s 2015 Employee Stock Purchase Plan.
VCEL (filed by Jonathan D. Siegal) reported a proposed sale of 3,433 shares of Common Stock under Rule 144, with proceeds shown as $130,454.00. The filing lists several prior issuer-side acquisitions (ESPP purchases and restricted stock vesting) with specific lot sizes and dates.
Vericel Corporation reported a Form 144 notice indicating a proposed sale of 5,000 shares of Common Stock. The filing lists Fidelity Brokerage Services LLC and a dollar value of $202,500.00, with the filing date shown as 05/07/2026. The record also shows restricted stock vesting of 1,733 shares on 02/18/2025 and 3,267 shares on 02/22/2025.
Vericel Corporation reported first-quarter 2026 results with total revenue of $68.4 million, up 30% from $52.6 million a year earlier, driven by strong growth in MACI and Epicel. Net loss narrowed to $6.3 million, or $0.12 per share, from $11.2 million.
MACI revenue rose to $56.4 million and Epicel to $10.9 million, while NexoBrid contributed $1.1 million. Vericel ended the quarter with $109.3 million in cash and cash equivalents and $101.3 million in investments, and had no borrowings under its $150 million revolving credit facility.
The company also entered a ten-year agreement with BARDA valued at up to $196.9 million to procure NexoBrid, build vendor-managed inventory, and fund development work, including a potential blast trauma indication and U.S.-based manufacturing capabilities.
Vericel Corporation reported strong growth for the first quarter of 2026, with total revenue up 30% to $68.4 million compared to $52.6 million a year earlier. MACI net revenue rose 22% to $56.4 million and Burn Care revenue grew 91% to $12.0 million, including Epicel revenue growth of 119%.
Gross margin improved to 72%, helping narrow the net loss to $6.3 million, or $0.12 per diluted share, from $11.2 million, or $0.23 per share. Non-GAAP adjusted EBITDA increased 195% to $9.6 million, and free cash flow reached $15.1 million.
The company ended the quarter with approximately $211 million in cash and investments and no debt. Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 to $336 million, with higher targets for both MACI and Burn Care.